Inotiv, Inc. is a contract research company, which is engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. The RMS segment offer access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
BörsenkürzelNOTV
Name des UnternehmensInotiv Inc
IPO-datumNov 25, 1997
CEOMr. Robert W. Leasure, Jr.
Anzahl der mitarbeiter1977
WertpapierartOrdinary Share
GeschäftsjahresendeNov 25
Addresse2701 Kent Ave
StadtWEST LAFAYETTE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl47906-1382
Telefon13174634527
Websitehttps://www.inotiv.com/
BörsenkürzelNOTV
IPO-datumNov 25, 1997
CEOMr. Robert W. Leasure, Jr.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten